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Background

• Checkpoint kinase 2 (CHEK2) is a tumor suppressor
gene that plays a crucial role in cell cycle regulation
and the response to DNA damage induced by
replication stress and double-stranded DNA breaks.
• CHEK2 protein is also required during mitosis for
spindle formation and accurate attachment of
kinetochores. Therefore, CHEK2 mutations can
contribute to errors in chromosome segregation,
leading to higher frequencies of unbalanced
structural rearrangements.
• Pathologic germline heterozygous mutations in
CHEK2 (c.1100delC) have been previously
associated with hereditary breast, prostate, kidney,
thyroid, and colon cancers.
• Congenital CHEK2 inactivation is also associated
with increased risk of myelodysplastic syndrome
(MDS) with poor prognosis. In addition to its roles
described above, a recent study demonstrated a
two times higher frequency of unbalanced
structural chromosomal rearrangements (58%)
among MDS patients harboring CHEK2 mutations in
comparison to non-carriers (27%).
• B-cell Acute Lymphoblastic Leukemia (B-ALL) has
never been described as a presenting manifestation
in patients with germline CHEK2 mutations.
• There is no published report of Tisagenlecleucel use
in patients with germline CHEK2 mutations.
• Long-term
studies
of
patients
receiving
Tisagenlecleucel have shown occurrence of MDS.
Whether this is secondary to CAR-T therapy
(therapy-related MDS) remains unknown.
• Therefore, we highlight the clinical dilemma of
differentiating the emergence of MDS-defining
cytogenetic abnormalities (deletion 7q) in a patient
with a germline CHEK2 mutation and already
predisposed to development of MDS, from any
possible CAR-T related MDS in this case report.

Case Report

• We describe a case of a pediatric patient with a pathologic germline CHEK2
mutation who was successfully treated with Tisagenlecleucel for relapsed BALL to avoid hematopoietic cell transplant (HCT). Timeline of clinical events
are depicted in Figure 1.
• A 12-year-old boy with a history of hypothyroidism was diagnosed with NCI
high-risk B-ALL, CNS-negative in February 2018. Cytogenetic analysis
revealed normal karyotype. FISH showed 93% positivity for CRLF2/P2RY8
rearrangement. He achieved total remission with COG AALL1131 therapy.
• In September 2018, evaluation of a new thyroid mass was diagnostic of
papillary thyroid carcinoma (Figure 2C) with no evidence of metastatic
disease. The patient underwent a total thyroidectomy with central lymph
node biopsy and radioactive iodine therapy.
• Genetic testing revealed a c.1100delC (p. Thr367Merts*15) mutation in the
CHEK2 gene. Both the patient’s biologic mother and fraternal twin brother
carry the same mutation with no history of malignancy (Figure 3). Biological
father was not available for genetic testing. The genetic panel also identified
three variants of unclear significance: CDKN2A (c.370C>T; p. Arg124Cys),
FLCN (c.62G>A (p. Cys21Tyr) and SDHAF2 (c.139A>G (p. Met47Val).
• In May 2019, during the maintenance phase of chemotherapy, the patient
presented with intolerable headaches and was diagnosed with medullary
and extramedullary relapse of CD19+ B-ALL. He was subsequently treated
with Tisagenlecleucel in September 2019 to avoid HCT. Post-infusion
complications of CRS and ICANS with max score of 2 responded completely
to corticosteroids, Tocilizumab, and Anakinra.
• Serial lumbar punctures and bone marrow (BM) aspirates and biopsies since
infusion have been negative for B-ALL (Figure 2A/2B). The patient continues
to be in remission except for findings of mild dysplasia on BM biopsy with
observation of a metaphasic clones with 7q deletion (Figure 2D).
• BM aspirate at 30-months post CAR-T infusion, in April 2022, revealed
immunophenotypic and NGS-negative remission and continued evidence of
partial deletion of the distal portion of 7q (only by karyotyping, not by FISH).
• This patient continues to be followed by serial BM aspirates/biopsy and LP
every 4 months. Disease monitoring via flow cytometry, cytogenetics, and
Next Generation Sequencing (NGS; ClonoSeq, Adaptive).
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Figure 2

A. Bone marrow aspirate (1000X) with single blast
and neutrophil with cytoplasmic vacuoles
B. Bone marrow biopsy (H&E, 200X) with no overt
dysplasia or blasts
C. Thyroid papillary carcinoma, H&E 100X
D. Bone marrow karyotype with partial deletion of 7q

• CAR-T therapy can be considered for treatment of
relapsed/refractory (R/R) B-ALL as a means of avoiding
HCT in patients with cancer predisposition syndromes.
• The risk of developing MDS can be 2-4 times higher in
germline CHEK2-mutation positive patients.
• MDS as a possible long-term complication of CAR-T cell
therapy has been described before and remains a
poorly understood phenomenon.
• The development of secondary malignancies following
CAR-T therapy is worrisome. However, in our patient
with a germline CHEK2 mutation, it is hard to ascertain
the true etiology for MDS defining cytogenetic
abnormalities, especially as our patient does not meet
the formal criteria for diagnosing MDS.
• R/R pediatric B-ALL patients treated with HCT after
CAR-T infusion have a significantly greater median
survival than the non-transplant group. However, the
utility of HCT for patients in deep remission with
showing no (zero) leukemic clones remains uncertain.
Therefore, in our patient with NGS negative remission,
we have taken the approach of close monitoring with
NGS testing without HCT.

